Author / anya
21 injections, results of which were published
Yesterday, 26 may, shanxi province's central bid network for medicines published the results of the proposed selection of the first group of drug syndicates for centralized procurement。
The pilot lead procurement in shanxi province involved 21 products and 17 pharmaceutical companies, with the selected drugs including pareszeb and head sidine produced by the shandong rohin pharmaceutical industry; ammonia bromine produced by silver lakes of stone medicine; dositasai of zilu pharmaceuticals; and tonalsijon。
Of these, the shandong rohin pharmaceutical industry won six drug winners for the shipment。
On 20 april, shanxi province officially launched the first group of drug syndicates for centralized procurement, which will be contracted on the basis of 70 per cent of the total procurement volume of the generic drug procurement platform for shanxi province, based on the products selected by the udps within one year (1 january 2019-31 december 2019)。
In this central procurement catalogue, 21 drugs were injectable. In shanxi province, the winning rule is relatively simple: the "minimum price winning":
There are more than three enterprises that have passed the qualification test, and the lowest number of enterprises that have received the requested qualifications after confirmation by both parties; if the number of enterprises that have passed the qualification check is less than three, two or one, the group of negotiating experts negotiates with the lowest bidder to reach an agreement and the enterprise acquires the qualifications to be selected; and if there is no agreement, the type is subject to drift。
In addition, the explicit requirement for declarations to encourage enterprises with raw drugs and reference preparations to participate in the declaration, without distinction as to quality level, to bring together raw drugs, over-rated medicines and unevaluated medicines, to a certain extent not conducive to effective price competition, and the end result is clear — in the list of winnings, few of which are successful。
How's the drop
Although the official figures are not published, according to some media disclosures, businesses are still facing a price war as a result of this lead procurement in shanxi province。
According to the wind cloud, the price range of the winning price range is 0. 4-0. 5 yuan for a country such as the left oxen fluoride, with a projected reduction of more than 50 per cent in the overall range of the volume procured this time。
The cyberblue database uses the key term "left oxyfluza injection fluids of hydrochloric acid" and has 83 national documents, 33 manufacturers。
In shanxi province, 114 bid messages were submitted for this variety, and the selected price was not published. There are 12 bid messages for the medicine of wu chinese suzhou。
Of these, for example, using the specifications for registration in this procurement catalogue (2ml; 0. 2g), the u-china medicines suzhou pharmaceutical product was awarded a price of 0. 88 yuan in shanxi, or more than 50 per cent if the net price of 0. 4-0. 5 yuan is real。
So, what if the price range in gisitas is between $21 and $22
Sabran was consulted on the minet database with the keyword "injecting gitabins with hydrochloride", a variety of 29 national documents and 19 manufacturers. There are 94 bids in shanxi province。
The successful drug, the jahalin organism, has a table of information, dated december 2015, for a 0. 2g-specified drug with a value of $90, a 70 per cent reduction。
In terms of the pattern of drug competition in shanxi province, the minet database shows that the 0. 2g-specifier injection of gitabin hydrochloride over the past five years has resulted in 39 tenders。
Among them, a number of enterprises, such as the beijing pharmaticals, the nanjing ching tianqing pharmaceuticals, harbin chongcheng pharmaceuticals, rohin pharmaceuticals, osaicon pharmaceuticals and jiangsu hauseng pharmaceuticals, and ziru pharmaceuticals, have bid information ranging from $40 to $330. This time, the hedge biological winner was able to obtain its guaranteed amount in shanxi province at a price in exchange for volume。
Injection belt procurement
While most of the previous two national catalogues were dominated by oral formulations, there is a view within the industry that all the varieties procured in shanxi province were injectables or that testing water was provided for the future inclusion of more injection varieties in the national collection。
According to data, injections account for more than 60 per cent of the drug market in public hospitals in china, of which they reach 70 per cent, with more than 33,000 permits for injections。
According to national securities data, the size of the injection market in 2018 had exceeded trillion yuan, of which billions were sold annually. To a certain extent, the amount and volume of the injection belt purchased was high and was consistent with the selection of varieties procured by the provinces, making it very easy to become a vector purchase。
In shanxi province, the selection of varieties, the offer by the enterprise and the final price reduction were extremely relevant to the subsequent pilot in the province of shanxi, which was the first to pilot the full injection variety in the provincial mass procurement。
In addition, the medical data from the swarm show that, as at 15 may, there were 32,100 approved document numbers for chemical imitating injections, covering 820 varieties and nearly 800 pharmaceutical companies. Only 33 varieties of 27 pharmaceutical companies were evaluated for consistency, and the overall rate of success was only 4 per cent。
There have been several evaluations of the consistency of injecting drug use, and the data of the network show that, as at 18 may 2020, the total number of generic drug consistency assessment admissions had been listed at 2052 and the total number of injecting drug consistency evaluations at 721。
Of these, the greatest number of sodium sulphate was injected, with 41 intake numbers, followed by a dose of 33 bromosortium hydrochloride。
The post-conformity evaluation, which is a national entry ticket for the future, has been successfully sampled by shanxi, which has resulted in price swaps, squeezing water and lowering the price of medicines。
In the context of the consistent evaluation of injections becoming on track, how will future provinces be able to conduct belt collections of injectables? Which injectors will be included in the list of varieties collected in the third national collection? This has affected future trends in the size of the market for the formulation, which will continue to be of concern to sabran。
